These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24844782)

  • 1. Howell-Jolly body-like inclusions in immunocompromised patients with antiviral treatment.
    Morales-Indiano C; Arenillas Rocha L; Mas Bosch V; Florensa Brichs L
    Ann Hematol; 2014 Dec; 93(12):2091-2. PubMed ID: 24844782
    [No Abstract]   [Full Text] [Related]  

  • 2. Ultrastructural changes in peripheral blood neutrophils in a patient receiving ganciclovir for CMV pneumonitis following allogenic bone marrow transplantation.
    Ghosh K; Muirhead D; Christie B; Hiwase D
    Bone Marrow Transplant; 1999 Aug; 24(4):429-31. PubMed ID: 10467335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Howell-Jolly body-like inclusions in neutrophils of a patient with a myelodysplastic syndrome.
    Mattana Dionisio L; Koehler J; de Faria Moss M
    Br J Haematol; 2021 Mar; 192(5):799. PubMed ID: 33216366
    [No Abstract]   [Full Text] [Related]  

  • 4. Howell-jolly body-like inclusions in neutrophils of a transplant recipient in association with ganciclovir therapy.
    Abdel-Monem H; Prakasam A; Thiagarajan P
    Arch Pathol Lab Med; 2010 Jun; 134(6):809-10. PubMed ID: 20524856
    [No Abstract]   [Full Text] [Related]  

  • 5. Howell-Jolly body-like inclusions in the neutrophils of patients with acquired immunodeficiency syndrome.
    Slagel DD; Lager DJ; Dick FR
    Am J Clin Pathol; 1994 Apr; 101(4):429-31. PubMed ID: 8160631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Howell-Jolly Body-Like Inclusions in Neutrophils of Patients With Myelodysplastic Syndrome: A Novel Correlation.
    Tong YT; Nguyen ND; Wahed A
    Arch Pathol Lab Med; 2019 Jan; 143(1):112-114. PubMed ID: 30059259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST
    Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antiviral drugs].
    Ruutu P
    Duodecim; 1991; 107(10):779-89. PubMed ID: 1364721
    [No Abstract]   [Full Text] [Related]  

  • 9. Acyclovir-resistant varicella-zoster virus keratitis in an immunocompetent patient.
    Gueudry J; Boutolleau D; Gueudin M; Burrel S; Miri A; Bodaghi B; Muraine M
    J Clin Virol; 2013 Sep; 58(1):318-20. PubMed ID: 23756055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selenoacyclovir and Selenoganciclovir: Discovery of a New Template for Antiviral Agents.
    Sahu PK; Umme T; Yu J; Nayak A; Kim G; Noh M; Lee JY; Kim DD; Jeong LS
    J Med Chem; 2015 Nov; 58(21):8734-8. PubMed ID: 26460883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-infective therapy for viral pneumonia.
    Mahmood W; Sacks SL
    Semin Respir Infect; 1995 Dec; 10(4):270-81. PubMed ID: 8668855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic antivirals in herpesvirus infections.
    Sasadeusz JJ; Sacks SL
    Dermatol Clin; 1993 Jan; 11(1):171-85. PubMed ID: 8382122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Resistance to virostatic agents in Herpes viruses: mechanism, incidence and clinical significance].
    Reusser P
    Schweiz Med Wochenschr; 1994 Jan; 124(4):152-8. PubMed ID: 8128197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fine structure of cells infected with human cytomegalovirus after treatment with 9-(1,3-dihydroxy-2-propoxymethyl)guanine.
    Mobberley MA; Ryder TA; Hart H; Tyms AS
    J Gen Virol; 1987 Jun; 68 ( Pt 6)():1553-62. PubMed ID: 3035059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorosubstitution and 7-alkylation as prospective modifications of biologically active 6-aryl derivatives of tricyclic acyclovir and ganciclovir analogues.
    Ostrowski T; Golankiewicz B; De Clercq E; Balzarini J
    Bioorg Med Chem; 2005 Mar; 13(6):2089-96. PubMed ID: 15727862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunocompromised patients, herpes zoster and acyclovir.
    Elder M; Thomas MG; Ellis-Pegler RB
    N Z Med J; 1996 May; 109(1022):196. PubMed ID: 8657394
    [No Abstract]   [Full Text] [Related]  

  • 17. Howell-Jolly body-like inclusions.
    Godwin JH
    Am J Clin Pathol; 1994 Sep; 102(3):389-90. PubMed ID: 8085564
    [No Abstract]   [Full Text] [Related]  

  • 18. Synthesis and fluorescent properties of 6-(4-biphenylyl)-3,9-dihydro-9-oxo-5H-imidazo[1,2-a]purine analogues of acyclovir and ganciclovir.
    Goslinski T; Wenska G; Golankiewicz B; Balzarini J; De Clercq E
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):911-4. PubMed ID: 14565309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ganciclovir and acyclovir on vascular cell proliferation of cytomegalovirus-positive and negative donors.
    Mohacsi PJ; Hulliger B; Wijngaard PL
    Transplant Proc; 1996 Dec; 28(6):3234-5. PubMed ID: 8962251
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiviral susceptibility of Herpes simplex viruses and its clinical correlates: a single center's experience.
    Rabella N; Otegui M; Labeaga R; Rodríguez P; Margall N; Gurguí M; Prats G
    Clin Infect Dis; 2002 Apr; 34(8):1055-60. PubMed ID: 11914993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.